Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488549 | 0.91 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL25301931 | 0.91 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL25256463 | 0.91 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL30833904 | 0.87 | NLRP3 (0.38) | NLRP3CCNKCDK7CCNHMNAT1 | |
| SCHEMBL30893679 | 0.85 | BTK (0.41) | NLRP3 | |
| SCHEMBL30834038 | 0.85 | BTK (0.41) | NLRP3 | |
| SCHEMBL25862360 | 0.85 | BTK (0.41) | NLRP3 | |
| SCHEMBL25303600 | 0.81 | NLRP3 (0.38) | NLRP3CCNKCDK7CCNHMNAT1 | |
| SCHEMBL25303599 | 0.81 | NLRP3 (0.38) | NLRP3CCNKCDK7CCNHMNAT1 | |
| SCHEMBL30488514 | 0.81 | NLRP3 (0.38) | NLRP3CCNKCDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |